Citation

Furtado I, Valdoleiros SR, Fragoso J, Vasconcelos O, Gonçalves MJ, Sarmento-Castro R. HIV and AIDS Review 2022; 21(1): 10-16.

Copyright

(Copyright © 2022)

DOI

10.5114/hivar.2022.112580

PMID

unavailable

Abstract

INTRODUCTION: Dolutegravir (DTG) is an effective antiretroviral drug, associated with rapid virologic responses. Intermittent viremia has been linked to a higher risk of virologic failure and immune activation. Material and methods: A retrospective, observational study of human immunodeficiency virus type 1 (HIV-1) infected adults who have started DTG between May 2015 and May 2017 was conducted, aiming to evaluate virologic responses. Baseline, 4-, 12-, 24-, and 48-week data were analyzed, including incidence of blips and low-level viremia (LLV), immunological progression and tolerability. The population was divided into three groups, including antiretroviral treatment (ART)-naïve, ART-experienced without virological failure (HIV-RNA < 200 copies/ml) at switch to DTG, and ART-experienced with virological failure (HIV-RNA ≥ 200 copies/ml) at switch to DTG.

RESULTS: Within the 227-patient population, 55 (24.2%) were ART-naïve and 172 (75.7%) switched from other regimens. Virologic suppression (< 50 copies/ml) at 48-week was observed in 92.7%, 88.4%, and 75% of naïve, ART-experienced without virological failure at switch, and ART-experienced with virological failure at switch patients, respectively. During follow-up, 4.9% of ART-experienced without virological failure patients had blips above 50 copies/ml, and 0.6% of them maintained LLV above 50 copies/ml.

CONCLUSIONS: The use of dolutegravir in naïve patients was associated with a 92.7% rate of viral suppression at week 48. Experienced non-failing patients rarely developed intermittent viremia above 50 copies/ml. © 2022 Termedia Publishing House Ltd.. All rights reserved.

Language: en

Keywords

adult; human; female; male; incidence; insomnia; suicide attempt; HIV; antiretroviral therapy; major clinical study; controlled study; retrospective study; headache; anxiety disorder; sleep disorder; gastrointestinal symptom; drug safety; follow up; drug efficacy; diarrhea; drug tolerability; drug withdrawal; primidone; treatment failure; Human immunodeficiency virus 1; virus load; Article; observational study; Human immunodeficiency virus infected patient; ejaculation disorder; lamivudine plus zidovudine; Human immunodeficiency virus 1 infection; dolutegravir; Dolutegravir; darunavir plus ritonavir; Antiretroviral agents; HIV integrase strand-transfer inhibitors; Low-level viremia; Viral blips; Virologic failure